LIVEBETTER Study Comparing Beta-Blocker and Calcium Channel Blocker Treatments for Older Adults with Stable Angina and Multiple Chronic Conditions

What this Trial Is About

Researchers are evaluating the effectiveness and tolerability of standard anti-anginal medications, specifically beta-blockers and calcium channel blockers, in older adults who have symptomatic Stable Ischemic Heart Disease SIHD along with multiple chronic conditions MCC. This pragmatic, single-blind, randomized trial aims to fill gaps in current guidelines by comparing these treatments in terms of symptom relief, function, quality of life, and safety. The study also explores caregiver burden and cognitive outcomes as part of an ancillary neurocognitive study. Participants are randomly assigned to receive either beta-blocker or calcium channel blocker therapy, with the choice and dosing of specific drugs determined by their treating clinicians following clinical guidelines. Both treatments are administered orally in pill form. The main study includes four visits over 12 months involving interviews, a six-minute walk test, and medical record reviews. An ancillary neurocognitive study extends follow-up to 24 months to assess cognitive decline and incidence of mild cognitive impairment or dementia. During the study, participants will undergo assessments such as quality of life surveys using EQ-5D-5L and PROMIS Scale, angina control evaluations with the Seattle Angina Questionnaire, and caregiver burden inventories. Physical function is measured by a six-minute walk test. Medication adherence and persistence will be monitored up to six months. Safety and tolerability are evaluated throughout, with follow-up visits scheduled to track long-term outcomes related to both heart and cognitive health.

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions